Total Payments
$4,375
2024 Payments
$875.43
Companies
35
Transactions
303
Medicare Patients
3,851
Medicare Billing
$326,892
Payment Breakdown by Category
Food & Beverage$4,037 (92.3%)
Education$338.29 (7.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,037 | 279 | 92.3% |
| Education | $338.29 | 24 | 7.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $891.93 | 84 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $692.68 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $486.59 | 29 | $0 (2024) |
| Genentech USA, Inc. | $279.11 | 18 | $0 (2023) |
| Merck Sharp & Dohme LLC | $263.34 | 13 | $0 (2024) |
| Celgene Corporation | $157.52 | 8 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $149.22 | 2 | $0 (2024) |
| Exelixis Inc. | $147.65 | 10 | $0 (2019) |
| Amgen Inc. | $126.61 | 8 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $119.80 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $875.43 | 52 | Novartis Pharmaceuticals Corporation ($167.20) |
| 2023 | $237.53 | 13 | PFIZER INC. ($57.61) |
| 2022 | $212.63 | 13 | Myovant Sciences Inc. ($44.34) |
| 2021 | $23.42 | 2 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $297.88 | 19 | PFIZER INC. ($65.27) |
| 2019 | $979.92 | 74 | PFIZER INC. ($201.56) |
| 2018 | $1,086 | 73 | PFIZER INC. ($267.46) |
| 2017 | $662.26 | 57 | PFIZER INC. ($165.25) |
All Payment Transactions
303 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $19.85 | General |
| 12/06/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $7.60 | General |
| Category: Oncology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.33 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.89 | General |
| Category: Oncology | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Oncology | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.89 | General |
| Category: Oncology | ||||||
| 10/31/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Oncology | ||||||
| 10/25/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.52 | General |
| Category: Cardiovascular | ||||||
| 10/09/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $20.69 | General |
| 10/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.73 | General |
| Category: Hematology | ||||||
| 10/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.84 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $14.79 | General |
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.89 | General |
| Category: Oncology | ||||||
| 08/27/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 973 | 1,263 | $246,225 | $91,672 |
| 2022 | 12 | 874 | 1,128 | $192,289 | $75,592 |
| 2021 | 10 | 893 | 1,177 | $161,975 | $72,606 |
| 2020 | 11 | 1,111 | 1,631 | $223,366 | $87,023 |
Total Patients
3,851
Total Services
5,199
Medicare Billing
$326,892
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 412 | 606 | $117,564 | $43,874 | 37.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 119 | 135 | $36,731 | $13,331 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 203 | 219 | $28,974 | $10,143 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 54 | 54 | $14,486 | $5,639 | 38.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 47 | 92 | $13,288 | $5,609 | 42.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 31 | $12,450 | $4,030 | 32.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 24 | $6,913 | $2,585 | 37.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 25 | $5,163 | $2,344 | 45.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 12 | 14 | $2,964 | $1,259 | 42.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 16 | 16 | $2,655 | $979.20 | 36.9% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 12 | 12 | $2,421 | $787.68 | 32.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 15 | $1,175 | $588.90 | 50.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 20 | 20 | $1,442 | $503.10 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 279 | 362 | $69,406 | $27,520 | 39.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 271 | 304 | $38,459 | $15,278 | 39.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 83 | 184 | $26,577 | $10,241 | 38.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 49 | 59 | $16,053 | $6,302 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 45 | 45 | $12,060 | $4,793 | 39.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 36 | 38 | $7,665 | $2,978 | 38.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 24 | $4,956 | $1,882 | 38.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $5,221 | $1,832 | 35.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 24 | 24 | $3,968 | $1,529 | 38.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 12 | $3,322 | $1,391 | 41.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 24 | 44 | $3,445 | $1,350 | 39.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 19 | 19 | $1,156 | $494.58 | 42.8% |
About Dr. Kelli Cawley, MD
Dr. Kelli Cawley, MD is a Hematology & Oncology healthcare provider based in Belpre, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023113727.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kelli Cawley, MD has received a total of $4,375 in payments from pharmaceutical and medical device companies, with $875.43 received in 2024. These payments were reported across 303 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($4,037).
As a Medicare-enrolled provider, Cawley has provided services to 3,851 Medicare beneficiaries, totaling 5,199 services with total Medicare billing of $326,892. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Belpre, OH
- Active Since 09/14/2006
- Last Updated 07/14/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023113727
Products in Payments
- OPDIVO (Biological) $515.92
- IBRANCE (Drug) $310.22
- XTANDI (Drug) $309.50
- KEYTRUDA (Biological) $237.16
- KISQALI (Drug) $228.76
- Cabometyx (Drug) $147.65
- XALKORI (Drug) $146.60
- Alecensa (Biological) $117.77
- INLYTA (Drug) $113.82
- MEKINIST (Drug) $102.04
- EMPLICITI (Biological) $97.32
- Imbruvica (Drug) $95.09
- BOSULIF (Drug) $74.33
- TECENTRIQ (Biological) $64.41
- ORGOVYX (Drug) $63.07
- DARZALEX (Biological) $59.21
- Nerlynx (Drug) $55.94
- Bavencio (Biological) $53.25
- Avastin (Biological) $52.50
- SCEMBLIX (Drug) $47.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.